Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses

1992 ◽  
Vol 8 (2) ◽  
pp. 132-143 ◽  
Author(s):  
Cindy Starbuck ◽  
Douglas A. Lauffenburger
Keyword(s):  
Mathematical Model ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Receptor Trafficking ◽  
Fibroblast Proliferation ◽  
Epidermal Growth

scholarly journals The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking

Oncotarget ◽  
2017 ◽  
Vol 8 (20) ◽  
pp. 33316-33328 ◽  
Author(s):  
Akio Soeda ◽  
Justin Lathia ◽  
Brian J. Williams ◽  
Qiulian Wu ◽  
Joseph Gallagher ◽  
...  
Keyword(s):  
Stem Cells ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Signaling Pathway ◽  
Growth Factor Receptor ◽  
Receptor Trafficking ◽  
Glioma Stem Cells ◽  
Epidermal Growth

Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors

2014 ◽  
Vol 13 (11) ◽  
pp. 2559-2571 ◽  
Author(s):  
Khalil Dayekh ◽  
Stephanie Johnson-Obaseki ◽  
Martin Corsten ◽  
Patrick J. Villeneuve ◽  
Harmanjatinder S. Sekhon ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Receptor Trafficking ◽  
Egfr Inhibitors ◽  
Synergistic Cytotoxicity ◽  
Epidermal Growth

scholarly journals The Phosphoinositide Kinase PIKfyve Mediates Epidermal Growth Factor Receptor Trafficking to the Nucleus

2007 ◽  
Vol 67 (19) ◽  
pp. 9229-9237 ◽  
Author(s):  
Jayoung Kim ◽  
Wan Jin Jahng ◽  
Dolores Di Vizio ◽  
Julie S. Lee ◽  
Raj Jhaveri ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Receptor Trafficking ◽  
Phosphoinositide Kinase ◽  
Epidermal Growth

Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients

2004 ◽  
Vol 22 (9) ◽  
pp. 1646-1654 ◽  
Author(s):  
Tania Crombet ◽  
Marta Osorio ◽  
Teresa Cruz ◽  
Carlos Roca ◽  
Ramón del Castillo ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Monoclonal Antibody ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Head And Neck ◽  
Growth Factor Receptor ◽  
Normal Tissues ◽  
Epidermal Growth ◽  
Receptor Monoclonal Antibody

Purpose To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy (RT) in unresectable head and neck cancer patients. Secondary end points were the measurement of h-R3 serum levels and the assessment of the potential mechanisms of antitumor effect on patient biopsies. Anti-idiotypic response to h-R3 was assessed. To predict pharmacologic effect, a mathematical model for antibodies recognizing antigens expressed in tumors and normal tissues was built. Patients and Methods Twenty-four patients with advanced carcinomas of the head and neck received six once-weekly infusions of h-R3 at four dose levels in combination with RT. Pretreatment tumor biopsies were obtained to evaluate epidermal growth factor receptor expression as an enrollment criterion. Second biopsies were taken to evaluate the proliferative activity and angiogenesis in comparison with the pretreatment samples. Patient serum samples were collected to measure h-R3 levels and anti-idiotypic response. Results The combination of h-R3 and RT was well tolerated. Antibody-related adverse events consisted in infusion reactions. No skin or allergic toxicity appeared. Overall survival significantly increased after the use of the higher antibody doses. Immunohistochemistry studies of tumor specimens before and after treatment revealed that antitumor response correlated with antiproliferative and antiangiogenic effect. One patient developed antibodies to h-R3. The mathematical model predicted that the maximum difference between the area under the curve in tumors and normal tissues is reached when the antibody has intermediate affinity. Conclusion h-R3 is a well-tolerated drug that may enhance radiocurability of unresectable head and neck neoplasms.

Sign in / Sign up

Export Citation Format

Share Document